CD4  + and CD8 + T-lymphocyte number as predictive marker of relapse after rituximab treatment in childhood-onset refractory nephrotic syndrome

ConclusionsLower CD4  + and CD8 + cell counts in the early phase after rituximab administration may predict a lower risk of relapse.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research